

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	WBC (10 ³ /uL)	8.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	1	1	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	8	8	WBC (10 ³ /uL)	3.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	29	30	WBC (10 ³ /uL)	3.5 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	36	38	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Creatinine (mg/dL)	0.61	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	PT (seconds)	10.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	PTT (seconds)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Platelets (10 ³ /uL)	248	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Platelets (10 ³ /uL)	251	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Platelets (10 ³ /uL)	235	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Platelets (10 ³ /uL)	272	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	WBC (10 ³ /uL)	3.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	Alkaline Phosphatase (U/L)	36	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	Alkaline Phosphatase (U/L)	32	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	Alkaline Phosphatase (U/L)	41	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Hemoglobin (g/dL)	11.1 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	Hemoglobin (g/dL)	10.5 (Mild)	RELATED	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	Hemoglobin (g/dL)	10.3 (Mild)	RELATED	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	Hemoglobin (g/dL)	10.6 (Mild)	RELATED	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	PT (seconds)	9.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	PTT (seconds)	27	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Platelets (10 ³ /uL)	307	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Platelets (10 ³ /uL)	254	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	Platelets (10 ³ /uL)	251	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	Platelets (10 ³ /uL)	243	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	Platelets (10 ³ /uL)	297	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	Serum Lipase (U/L)	47.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	Serum Lipase (U/L)	51.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	Serum Lipase (U/L)	46.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	Total Bilirubin (mg/dL)	0.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	WBC (10 ³ /uL)	4.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	WBC (10 ³ /uL)	3.4 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	WBC (10 ³ /uL)	3.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	WBC (10 ³ /uL)	3.3 (Mild)	RELATED	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	WBC (10 ³ /uL)	3.8	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Creatinine (mg/dL)	1.06	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Hemoglobin (g/dL)	12.9 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	PT (seconds)	10.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	PTT (seconds)	31	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Platelets (10 ³ /uL)	240	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Platelets (10 ³ /uL)	272	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Platelets (10 ³ /uL)	272	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	WBC (10 ³ /uL)	3.5 (Mild)	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	WBC (10 ³ /uL)	3.2 (Mild)	RELATED	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	WBC (10~{super 3}/uL)	4.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	WBC (10~{super 3}/uL)	4.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Alanine Aminotransferase (U/L)	38	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Alanine Aminotransferase (U/L)	66 (Mild)	NOT RELATED	increased alcohol night before	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Alanine Aminotransferase (U/L)	42	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Aspartate Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Creatinine (mg/dL)	1.22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Hemoglobin (g/dL)	15.3 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Hemoglobin (g/dL)	15.5 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	PT (seconds)	10.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	PTT (seconds)	32	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Platelets (10 ³ /uL)	232	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Serum Lipase (U/L)	8.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	WBC (10 ³ /uL)	8.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	Hemoglobin (g/dL)	11.5 (Mild)	NOT RELATED	Study procedure	NA-NOT APPLICABLE	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Study procedure	NA-NOT APPLICABLE	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	57	58	Hemoglobin (g/dL)	11.6 (Mild)	NOT RELATED	Phlebotomy	NA-NOT APPLICABLE	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	PT (seconds)	10.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	PTT (seconds)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Platelets (10 ³ /uL)	302	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Platelets (10 ³ /uL)	290	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Platelets (10 ³ /uL)	247	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	Platelets (10 ³ /uL)	234	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	Platelets (10 ³ /uL)	260	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	Serum Lipase (U/L)	61.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Study procedure	NA-NOT APPLICABLE	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	Study procedure	NA-NOT APPLICABLE	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	PT (seconds)	9.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	PTT (seconds)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Platelets (10 ³ /uL)	240	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Platelets (10 ³ /uL)	269	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Platelets (10 ³ /uL)	289	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Platelets (10 ³ /uL)	246	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Platelets (10 ³ /uL)	280	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	WBC (10 ³ /uL)	7.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	WBC (10 ³ /uL)	7.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	WBC (10 ³ /uL)	7.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	WBC (10 ³ /uL)	7.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	WBC (10 ³ /uL)	6.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Alkaline Phosphatase (U/L)	61	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	PT (seconds)	11.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	PTT (seconds)	29	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Platelets (10 ³ /uL)	280	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Platelets (10 ³ /uL)	253	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Platelets (10 ³ /uL)	231	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Platelets (10 ³ /uL)	255	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	WBC (10 ³ /uL)	4.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	WBC (10 ³ /uL)	2.9 (Mild)	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	WBC (10 ³ /uL)	3.2 (Mild)	RELATED	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	WBC (10 ³ /uL)	2.8 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	WBC (10 ³ /uL)	2.7 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Creatinine (mg/dL)	0.89	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	PT (seconds)	10.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Platelets (10 ³ /uL)	313	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Platelets (10 ³ /uL)	264	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Platelets (10 ³ /uL)	273	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Platelets (10 ³ /uL)	274	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	WBC (10 ³ /uL)	4.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	Alanine Aminotransferase (U/L)	48	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-7	Alanine Aminotransferase (U/L)	44	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	Alanine Aminotransferase (U/L)	43	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	36	36	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-7	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	41	36	36	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	Hemoglobin (g/dL)	16.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA-NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	41	36	36	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA-NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	Platelets (10 ³ /uL)	298	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	36	36	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	WBC (10 ³ /uL)	6.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	WBC (10 ³ /uL)	5.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	WBC (10 ³ /uL)	5.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	36	36	WBC (10 ³ /uL)	5.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Alanine Aminotransferase (U/L)	45	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Aspartate Aminotransferase (U/L)	45 (Mild)	NOT RELATED	Alcohol intake	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Creatinine (mg/dL)	0.71	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Hemoglobin (g/dL)	15.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	PT (seconds)	10.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Platelets (10~{super 3}/uL)	286	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Platelets (10~{super 3}/uL)	248	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Platelets (10~{super 3}/uL)	251	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Platelets (10~{super 3}/uL)	249	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Platelets (10~{super 3}/uL)	257	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	WBC (10~{super 3}/uL)	6.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	WBC (10~{super 3}/uL)	3.5 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Creatinine (mg/dL)	0.52	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Creatinine (mg/dL)	0.57	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Creatinine (mg/dL)	0.59	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Creatinine (mg/dL)	0.53	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Hemoglobin (g/dL)	12.7 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	PT (seconds)	10.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Platelets (10~ ³ /uL)	241	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Platelets (10~ ³ /uL)	249	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Platelets (10~ ³ /uL)	293	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Platelets (10~ ³ /uL)	224	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Platelets (10~ ³ /uL)	257	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	WBC (10~{super 3}/uL)	5.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	WBC (10~{super 3}/uL)	5.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	WBC (10~{super 3}/uL)	6.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Alanine Aminotransferase (U/L)	53 (Mild)	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Aspartate Aminotransferase (U/L)	38	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Hemoglobin (g/dL)	16.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Hemoglobin (g/dL)	14.7 (Moderate)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Hemoglobin (g/dL)	16.1 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Hemoglobin (g/dL)	16.2 (Mild)
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	PT (seconds)	10.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	PTT (seconds)	28	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Platelets (10 ³ /uL)	251	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Platelets (10 ³ /uL)	223	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Platelets (10 ³ /uL)	252	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Platelets (10~{super 3}/uL)	195	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Platelets (10~{super 3}/uL)	269	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	WBC (10~{super 3}/uL)	4.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	WBC (10~{super 3}/uL)	3.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	WBC (10~{super 3}/uL)	3.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Alanine Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Hemoglobin (g/dL)	13.4 (Mild)	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Hemoglobin (g/dL)	13.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	PT (seconds)	10.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Platelets (10 ³ /uL)	200	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Platelets (10~{super 3}/uL)	172	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Platelets (10~{super 3}/uL)	167	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Platelets (10~{super 3}/uL)	148	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Platelets (10~{super 3}/uL)	163	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	WBC (10~{super 3}/uL)	7.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	WBC (10~{super 3}/uL)	5.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Hemoglobin (g/dL)	14.9 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	PT (seconds)	10.8	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	PTT (seconds)	28	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Platelets (10~{super 3}/uL)	327	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Platelets (10~{super 3}/uL)	312	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Platelets (10~{super 3}/uL)	324	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Platelets (10~{super 3}/uL)	302	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Platelets (10~{super 3}/uL)	335	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Total Bilirubin (mg/dL)	1.6 (Mild)	NOT RELATED	suspected gilberts	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Total Bilirubin (mg/dL)	2.1 (Moderate)	NOT RELATED	suspected Gilberts	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Total Bilirubin (mg/dL)	1.8 (Mild)	NOT RELATED	Other	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	WBC (10~{super 3}/uL)	8.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	WBC (10~{super 3}/uL)	6.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	WBC (10~{super 3}/uL)	6.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	WBC (10~{super 3}/uL)	6.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Alkaline Phosphatase (U/L)	31	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Alkaline Phosphatase (U/L)	35	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Creatinine (mg/dL)	0.63	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Creatinine (mg/dL)	0.63	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Hemoglobin (g/dL)	11.6 (Mild)	RELATED	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	PT (seconds)	10.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	PTT (seconds)	30	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Platelets (10 ³ /uL)	234	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Platelets (10 ³ /uL)	209	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Platelets (10 ³ /uL)	200	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	WBC (10~{super 3}/uL)	6.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	WBC (10~{super 3}/uL)	4.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	WBC (10~{super 3}/uL)	4.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Hemoglobin (g/dL)	16.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Hemoglobin (g/dL)	14.8 (Mild)
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	PT (seconds)	10.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	PTT (seconds)	25	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Platelets (10 ³ /uL)	241	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Platelets (10 ³ /uL)	266	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Platelets (10 ³ /uL)	265	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Platelets (10~{super 3}/uL)	284	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Serum Lipase (U/L)	58.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Serum Lipase (U/L)	61.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Total Bilirubin (mg/dL)	1.5 (Mild)	RELATED	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	WBC (10~{super 3}/uL)	4.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	WBC (10~{super 3}/uL)	5.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	WBC (10~{super 3}/uL)	4.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Creatinine (mg/dL)	0.56	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Creatinine (mg/dL)	0.57	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Hemoglobin (g/dL)	13.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Hemoglobin (g/dL)	12.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	PT (seconds)	9.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	PTT (seconds)	27	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Platelets (10~{super 3}/uL)	317	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Platelets (10~{super 3}/uL)	278	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Platelets (10~{super 3}/uL)	281	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Platelets (10~{super 3}/uL)	301	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Total Bilirubin (mg/dL)	0.2	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Total Bilirubin (mg/dL)	0.2	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	WBC (10~{super 3}/uL)	7.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	WBC (10~{super 3}/uL)	7.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	WBC (10~{super 3}/uL)	5.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	WBC (10~{super 3}/uL)	6.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Alkaline Phosphatase (U/L)	105	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Alkaline Phosphatase (U/L)	122	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Alkaline Phosphatase (U/L)	105	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Alkaline Phosphatase (U/L)	106	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Alkaline Phosphatase (U/L)	93	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Hemoglobin (g/dL)	15.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Hemoglobin (g/dL)	16.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Hemoglobin (g/dL)	15.7 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Hemoglobin (g/dL)	16.2 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Hemoglobin (g/dL)	15.7 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	PT (seconds)	10.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	PTT (seconds)	28	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Platelets (10~{super 3}/uL)	199	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Platelets (10~{super 3}/uL)	207	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Platelets (10~{super 3}/uL)	190	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Platelets (10~{super 3}/uL)	174	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Platelets (10~{super 3}/uL)	190	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Alkaline Phosphatase (U/L)	40	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Alkaline Phosphatase (U/L)	36	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Alkaline Phosphatase (U/L)	40	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	PTT (seconds)	27	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Platelets (10~{super 3}/uL)	242	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Platelets (10~{super 3}/uL)	245	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Platelets (10~{super 3}/uL)	248	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Platelets (10~{super 3}/uL)	216	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Platelets (10~{super 3}/uL)	261	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	WBC (10~{super 3}/uL)	3.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	WBC (10~{super 3}/uL)	4.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	WBC (10~{super 3}/uL)	3.4 (Mild)	RELATED	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	WBC (10~{super 3}/uL)	4.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	PTT (seconds)	30	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Platelets (10 ³ /uL)	193	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Platelets (10 ³ /uL)	210	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	WBC (10~{super 3}/uL)	7.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	WBC (10~{super 3}/uL)	6.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	WBC (10~{super 3}/uL)	6.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	WBC (10~{super 3}/uL)	6.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Hemoglobin (g/dL)	13.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Hemoglobin (g/dL)	11.4 (Mild)	RELATED	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	PT (seconds)	10.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	PTT (seconds)	28	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Platelets (10 ³ /uL)	298	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Platelets (10 ³ /uL)	243	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Platelets (10 ³ /uL)	247	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Platelets (10~{super 3}/uL)	210	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Platelets (10~{super 3}/uL)	255	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Serum Lipase (U/L)	9.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	WBC (10~{super 3}/uL)	4.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	WBC (10~{super 3}/uL)	4.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	WBC (10~{super 3}/uL)	3.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Creatinine (mg/dL)	0.72	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	PTT (seconds)	26	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Platelets (10 ³ /uL)	189	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Platelets (10~{super 3}/uL)	202	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Platelets (10~{super 3}/uL)	193	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Platelets (10~{super 3}/uL)	216	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Platelets (10~{super 3}/uL)	221	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Serum Lipase (U/L)	9.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	WBC (10~{super 3}/uL)	7.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	WBC (10~{super 3}/uL)	6.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	WBC (10~{super 3}/uL)	6.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	WBC (10~{super 3}/uL)	6.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Creatinine (mg/dL)	1.11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Creatinine (mg/dL)	1.21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Hemoglobin (g/dL)	14.5 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	PT (seconds)	10.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	PTT (seconds)	28	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Platelets (10~{super 3}/uL)	185	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Platelets (10~{super 3}/uL)	200	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Platelets (10~{super 3}/uL)	210	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Serum Lipase (U/L)	51.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Serum Lipase (U/L)	45.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	WBC (10~{super 3}/uL)	6.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	WBC (10~{super 3}/uL)	6.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Alkaline Phosphatase (U/L)	61	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Creatinine (mg/dL)	0.76	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	PT (seconds)	9.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	PTT (seconds)	27	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Platelets (10~{super 3}/uL)	260	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Platelets (10~{super 3}/uL)	250	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Platelets (10~{super 3}/uL)	267	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Serum Lipase (U/L)	51.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Serum Lipase (U/L)	52.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Serum Lipase (U/L)	47.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	WBC (10~{super 3}/uL)	4.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	WBC (10~{super 3}/uL)	3.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	WBC (10~{super 3}/uL)	4.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	PTT (seconds)	26	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Platelets (10~{super 3}/uL)	203	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Platelets (10~{super 3}/uL)	211	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Platelets (10~{super 3}/uL)	230	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Serum Lipase (U/L)	67.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	WBC (10~{super 3}/uL)	4.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	WBC (10~{super 3}/uL)	4.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	PT (seconds)	9.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	PTT (seconds)	30	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Platelets (10 ³ /uL)	276	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Platelets (10 ³ /uL)	273	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Platelets (10 ³ /uL)	282	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	WBC (10~{super 3}/uL)	7.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	WBC (10~{super 3}/uL)	6.8	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Alkaline Phosphatase (U/L)	95	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alkaline Phosphatase (U/L)	87	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alkaline Phosphatase (U/L)	90	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	PT (seconds)	10.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Platelets (10 ³ /uL)	207	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Platelets (10~{super 3}/uL)	213	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Platelets (10~{super 3}/uL)	228	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Serum Lipase (U/L)	55.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Serum Lipase (U/L)	52.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	WBC (10~{super 3}/uL)	6.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	WBC (10~{super 3}/uL)	7.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Hemoglobin (g/dL)	13.1 (Mild)
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	PT (seconds)	9.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	PTT (seconds)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Platelets (10~{super 3}/uL)	442	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-15	Platelets (10~{super 3}/uL)	389	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Platelets (10~{super 3}/uL)	362	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Platelets (10~{super 3}/uL)	363	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	WBC (10~{super 3}/uL)	6.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Alanine Aminotransferase (U/L)	38	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alanine Aminotransferase (U/L)	33	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Alkaline Phosphatase (U/L)	92	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alkaline Phosphatase (U/L)	83	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	13.5 (Mild)	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	PTT (seconds)	26	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Platelets (10~{super 3}/uL)	151	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Platelets (10~{super 3}/uL)	153	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Platelets (10~{super 3}/uL)	188	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	WBC (10~{super 3}/uL)	3.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Alanine Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	PT (seconds)	11.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	PTT (seconds)	31	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Platelets (10 ³ /uL)	201	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Platelets (10 ³ /uL)	165	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Platelets (10 ³ /uL)	176	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Serum Lipase (U/L)	37.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	WBC (10~{super 3}/uL)	4.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Hemoglobin (g/dL)	11.9 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Hemoglobin (g/dL)	12.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	PT (seconds)	10.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	PTT (seconds)	31	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Platelets (10~{super 3}/uL)	191	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Platelets (10~{super 3}/uL)	200	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Serum Lipase (U/L)	67.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	WBC (10~{super 3}/uL)	3.5 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	WBC (10~{super 3}/uL)	3.3 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Alkaline Phosphatase (U/L)	40	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Hemoglobin (g/dL)	13.5 (Mild)	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	PT (seconds)	10.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	PTT (seconds)	26	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Platelets (10~{super 3}/uL)	366	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Platelets (10~{super 3}/uL)	333	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Platelets (10~{super 3}/uL)	354	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	WBC (10~{super 3}/uL)	6.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	WBC (10~{super 3}/uL)	6.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Creatinine (mg/dL)	0.55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Hemoglobin (g/dL)	12.0 (Mild)	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Hemoglobin (g/dL)	12.0 (Mild)
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	PTT (seconds)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Platelets (10~{super 3}/uL)	204	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Platelets (10~{super 3}/uL)	189	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Platelets (10~{super 3}/uL)	213	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	WBC (10~{super 3}/uL)	3.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-15	WBC (10~{super 3}/uL)	4.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	WBC (10~{super 3}/uL)	3.1 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	WBC (10~{super 3}/uL)	3.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Creatinine (mg/dL)	1.10	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Creatinine (mg/dL)	1.11	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Hemoglobin (g/dL)	13.0 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	PT (seconds)	9.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Platelets (10 ³ /uL)	196	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Platelets (10 ³ /uL)	208	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	WBC (10~{super 3}/uL)	6.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Hemoglobin (g/dL)	12.7 (Mild)
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	PT (seconds)	9.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	PTT (seconds)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Platelets (10 ³ /uL)	171	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Platelets (10~{super 3}/uL)	187	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Platelets (10~{super 3}/uL)	183	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	WBC (10~{super 3}/uL)	4.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Hemoglobin (g/dL)	13.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	PT (seconds)	9.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	PTT (seconds)	29	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Platelets (10~{super 3}/uL)	356	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Platelets (10~{super 3}/uL)	369	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Platelets (10~{super 3}/uL)	357	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	WBC (10~{super 3}/uL)	6.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	WBC (10~{super 3}/uL)	7.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Hemoglobin (g/dL)	13.7 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	PT (seconds)	10.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	PTT (seconds)	29	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Platelets (10 ³ /uL)	195	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Platelets (10 ³ /uL)	186	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Platelets (10 ³ /uL)	194	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	WBC (10~{super 3}/uL)	5.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	WBC (10~{super 3}/uL)	4.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Hemoglobin (g/dL)	11.0 (Mild)
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	PT (seconds)	10.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	PTT (seconds)	29	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Platelets (10 ³ /uL)	242	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Platelets (10 ³ /uL)	257	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Platelets (10 ³ /uL)	234	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	WBC (10~{super 3}/uL)	6.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Creatinine (mg/dL)	0.71	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Hemoglobin (g/dL)	12.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	PT (seconds)	9.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	PTT (seconds)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Platelets (10 ³ /uL)	281	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Platelets (10 ³ /uL)	318	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Platelets (10~{super 3}/uL)	303	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Total Bilirubin (mg/dL)	1.4 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	WBC (10~{super 3}/uL)	4.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	WBC (10~{super 3}/uL)	4.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	WBC (10~{super 3}/uL)	4.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Creatinine (mg/dL)	1.05	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	15.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	PT (seconds)	10.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	PTT (seconds)	28	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Platelets (10~{super 3}/uL)	211	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Platelets (10~{super 3}/uL)	213	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Platelets (10~{super 3}/uL)	213	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	WBC (10~{super 3}/uL)	6.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	WBC (10~{super 3}/uL)	5.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Aspartate Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Aspartate Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Aspartate Aminotransferase (U/L)	29	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	PT (seconds)	9.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	PTT (seconds)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Platelets (10~{super 3}/uL)	144	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Platelets (10~{super 3}/uL)	104 (Moderate)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Platelets (10~{super 3}/uL)	125 (Mild)	RELATED	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	WBC (10~{super 3}/uL)	6.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	WBC (10~{super 3}/uL)	6.5	N/A	N/A	N/A	N/A

**APPENDIX F:
Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	-1	-21	37.2	121	85	80	79.9	184.5
	250 mcg mRNA-1273 (18-55 years)	1	1	36.6	114	66	81	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.4	108	73	76	.	.
	250 mcg mRNA-1273 (18-55 years)	15	15	36.2	120	82	82	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	36.3	123	76	82	.	.
	250 mcg mRNA-1273 (18-55 years)	36	36	36.1	114	77	71	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	37.3	115	80	64	84.4	175.5
	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	110	76	64	.	.
	100 mcg mRNA-1273 (18-55 years)	8	7	36.4	130	82	79	.	.
	100 mcg mRNA-1273 (18-55 years)	15	14	37.1	130	82	102 (Mild)	.	.
	100 mcg mRNA-1273 (18-55 years)	29	28	36.4	128	80	73	.	.
	100 mcg mRNA-1273 (18-55 years)	36	35	36.6	119	82	75	.	.
	100 mcg mRNA-1273 (18-55 years)	43	42	36.3	121	79	80	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	57	55	37.1	126	83	63	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	37.1	137	98 (Moderate)	78	68.8	169.4
	100 mcg mRNA-1273 (18-55 years)	1	1	36.4	138	90	73	.	.
	100 mcg mRNA-1273 (18-55 years)	8	8	37.2	138	80	78	.	.
	100 mcg mRNA-1273 (18-55 years)	15	15	37.1	137	90	67	.	.
	100 mcg mRNA-1273 (18-55 years)	29	28	36.9	133	87	92	.	.
	100 mcg mRNA-1273 (18-55 years)	36	35	37.2	136	89	82	.	.
	100 mcg mRNA-1273 (18-55 years)	43	42	37.1	133	84	78	.	.
	100 mcg mRNA-1273 (18-55 years)	57	56	37.1	129	84	86	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.8	130	83	63	93	181.7
	100 mcg mRNA-1273 (18-55 years)	1	1	37	128	81	76	.	.
	100 mcg mRNA-1273 (18-55 years)	8	7	36.8	117	75	68	.	.
	100 mcg mRNA-1273 (18-55 years)	15	13	37.2	117	81	73	.	.
	100 mcg mRNA-1273 (18-55 years)	29	28	36.4	134	89	68	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	36	34	36.4	109	71	62	.	.
	100 mcg mRNA-1273 (18-55 years)	43	40	36.9	100	66	78	.	.
	100 mcg mRNA-1273 (18-55 years)	57	55	36.3	111	75	76	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.7	106	68	51 (Mild)	73.5	172
	100 mcg mRNA-1273 (18-55 years)	1	1	36.7	129	74	55	.	.
	100 mcg mRNA-1273 (18-55 years)	8	8	36.9	122	72	85	.	.
	100 mcg mRNA-1273 (18-55 years)	15	15	37.1	120	74	55	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	37.1	118	78	58	.	.
	100 mcg mRNA-1273 (18-55 years)	36	36	36.8	117	69	82	.	.
	100 mcg mRNA-1273 (18-55 years)	43	43	36.6	108	76	53 (Mild)	.	.
	100 mcg mRNA-1273 (18-55 years)	57	55	36.2	113	70	57	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	37.3	116	77	53 (Mild)	69.7	160.7
	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	114	78	53 (Mild)	.	.
	100 mcg mRNA-1273 (18-55 years)	8	8	37.1	101	67	56	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	15	13	37.1	109	67	91	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	37.3	106	76	83	.	.
	100 mcg mRNA-1273 (18-55 years)	36	35	37.6	107	66	80	.	.
	100 mcg mRNA-1273 (18-55 years)	43	42	36.9	110	74	96	.	.
	100 mcg mRNA-1273 (18-55 years)	57	56	36.9	108	74	66	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.9	137	81	63	76.1	170
	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	111	71	63	.	.
	100 mcg mRNA-1273 (18-55 years)	8	8	36.8	105	65	59	.	.
	100 mcg mRNA-1273 (18-55 years)	15	15	36.7	111	73	63	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	36.6	118	69	73	.	.
	100 mcg mRNA-1273 (18-55 years)	36	36	37	119	66	64	.	.
	100 mcg mRNA-1273 (18-55 years)	43	43	37.1	123	77	74	.	.
	100 mcg mRNA-1273 (18-55 years)	57	57	36.3	114	69	76	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-20	37.3	115	73	76	55.7	157.5

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	1	1	37.2	120	78	66	.	.
	250 mcg mRNA-1273 (18-55 years)	8	7	37.3	107	74	74	.	.
	250 mcg mRNA-1273 (18-55 years)	15	16	37.4	111	76	75	.	.
	250 mcg mRNA-1273 (18-55 years)	29	28	36.8	104	77	75	.	.
	250 mcg mRNA-1273 (18-55 years)	36	35	37	105	71	79	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-10	36.8	127	86	55	95.9	181.7
	250 mcg mRNA-1273 (18-55 years)	1	1	36.2	124	89	58	.	.
	250 mcg mRNA-1273 (18-55 years)	8	7	37.1	122	87	60	.	.
	250 mcg mRNA-1273 (18-55 years)	15	14	36.8	121	82	72	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	36.8	130	87	68	.	.
	250 mcg mRNA-1273 (18-55 years)	36	35	36.5	114	86	72	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-6	36.2	150 (Mild)	85	69	81.5	177
	100 mcg mRNA-1273 (56-70 years)	1	1	36.5	150 (Mild)	82	71	.	.
	100 mcg mRNA-1273 (56-70 years)	8	7	36.6	145 (Mild)	79	69	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	15	14	36.4	139	83	68	.	.
	100 mcg mRNA-1273 (56-70 years)	29	28	36.8	130	83	63	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.9	122	79	83	83.3	174.5
	100 mcg mRNA-1273 (56-70 years)	1	1	36.3	120	75	99	.	.
	100 mcg mRNA-1273 (56-70 years)	8	9	36.4	123	77	82	.	.
	100 mcg mRNA-1273 (56-70 years)	15	15	36.5	109	76	94	.	.
	100 mcg mRNA-1273 (56-70 years)	29	30	36.4	112	67	96	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-4	37.3	136	81	80	72.2	158.1
	25 mcg mRNA-1273 (56-70 years)	1	1	37.2	113	77	82	.	.
	25 mcg mRNA-1273 (56-70 years)	8	8	37.2	128	71	80	.	.
	25 mcg mRNA-1273 (56-70 years)	15	15	36.2	132	71	78	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	36.6	119	73	79	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.8	138	78	56	64.7	166.5
	25 mcg mRNA-1273 (56-70 years)	1	1	36.3	109	66	66	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	8	8	36.8	111	69	70	.	.
	25 mcg mRNA-1273 (56-70 years)	15	15	36.3	92	53	63	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	36.7	102	60	62	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.4	138	84	81	52	149
	25 mcg mRNA-1273 (56-70 years)	1	1	37	140	86	78	.	.
	25 mcg mRNA-1273 (56-70 years)	8	8	36.6	134	80	86	.	.
	25 mcg mRNA-1273 (56-70 years)	15	16	36.1	134	78	80	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	37	113	72	70	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.5	115	72	41 (Severe)	88.6	186
	25 mcg mRNA-1273 (56-70 years)	1	1	37	143 (Mild)	79	74	.	.
	25 mcg mRNA-1273 (56-70 years)	8	8	36.6	122	74	68	.	.
	25 mcg mRNA-1273 (56-70 years)	15	15	36.6	102	55	61	.	.
	25 mcg mRNA-1273 (56-70 years)	29	30	36.3	116	69	61	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.7	110	72	78	56.4	164.5

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	1	1	36.9	101	71	89	.	.
	100 mcg mRNA-1273 (56-70 years)	8	7	37.3	113	70	88	.	.
	100 mcg mRNA-1273 (56-70 years)	15	14	37.2	109	75	86	.	.
	100 mcg mRNA-1273 (56-70 years)	29	28	37.1	110	75	90	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.4	147 (Mild)	93 (Mild)	75	64.2	160.1
	100 mcg mRNA-1273 (56-70 years)	1	1	36.5	150 (Mild)	93 (Mild)	75	.	.
	100 mcg mRNA-1273 (56-70 years)	8	8	36.1	142 (Mild)	89	83	.	.
	100 mcg mRNA-1273 (56-70 years)	15	15	36.4	142 (Mild)	92 (Mild)	85	.	.
	100 mcg mRNA-1273 (56-70 years)	29	29	36.3	146 (Mild)	91 (Mild)	72	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-4	37.2	134	87	60	66.5	171
	100 mcg mRNA-1273 (56-70 years)	1	1	36.4	130	84	66	.	.
	100 mcg mRNA-1273 (56-70 years)	8	8	37	120	79	71	.	.
	100 mcg mRNA-1273 (56-70 years)	15	15	36.6	116	78	77	.	.
	100 mcg mRNA-1273 (56-70 years)	29	29	37.1	126	88	75	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	-1	-2	36.4	121	79	58	62	163.1
	25 mcg mRNA-1273 (56-70 years)	1	1	37.1	113	71	72	.	.
	25 mcg mRNA-1273 (56-70 years)	8	9	36.3	104	64	62	.	.
	25 mcg mRNA-1273 (56-70 years)	15	16	36.4	113	68	63	.	.
	25 mcg mRNA-1273 (56-70 years)	29	30	36.8	124	69	61	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-6	36.3	129	74	53 (Mild)	60.6	167.7
	100 mcg mRNA-1273 (56-70 years)	1	1	36.9	129	81	62	.	.
	100 mcg mRNA-1273 (56-70 years)	8	7	36.5	116	70	65	.	.
	100 mcg mRNA-1273 (56-70 years)	15	14	36.9	113	71	64	.	.
	100 mcg mRNA-1273 (56-70 years)	29	28	37.4	128	72	67	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.8	122	77	77	78.5	167.9
	100 mcg mRNA-1273 (18-55 years)	1	1	36.8	119	58	70	.	.
	100 mcg mRNA-1273 (18-55 years)	8	8	36.8	126	73	85	.	.
	100 mcg mRNA-1273 (18-55 years)	15	13	36.7	112	68	80	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	29	29	36.9	113	79	91	.	.
	100 mcg mRNA-1273 (18-55 years)	36	35	37.2	118	67	73	.	.
	100 mcg mRNA-1273 (18-55 years)	43	41	36.9	117	68	86	.	.
	100 mcg mRNA-1273 (18-55 years)	57	55	36.8	125	72	98	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.7	129	71	67	98.7	188
	100 mcg mRNA-1273 (18-55 years)	1	1	37.1	136	75	81	.	.
	100 mcg mRNA-1273 (18-55 years)	8	9	36.7	137	73	83	.	.
	100 mcg mRNA-1273 (18-55 years)	15	15	36.6	116	73	83	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	36.6	125	74	75	.	.
	100 mcg mRNA-1273 (18-55 years)	36	35	36.7	119	74	81	.	.
	100 mcg mRNA-1273 (18-55 years)	43	46					.	.
	100 mcg mRNA-1273 (18-55 years)	57	55					.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.8	140	92 (Mild)	85	81.6	172.7
	100 mcg mRNA-1273 (18-55 years)	1	1	36.7	138	83	85	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	8	8	36.7	136	84	85	.	.
	100 mcg mRNA-1273 (18-55 years)	15	15	37	138	90	86	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	36.7	123	87	68	.	.
	100 mcg mRNA-1273 (18-55 years)	36	36	37.1	136	87	84	.	.
	100 mcg mRNA-1273 (18-55 years)	43	43	36.8	129	77	70	.	.
	100 mcg mRNA-1273 (18-55 years)	57	57	36.9	139	81	94	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-2	36.7	142 (Mild)	70	78	77.1	177.8
	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	120	77	88	.	.
	100 mcg mRNA-1273 (18-55 years)	8	8	36.7	129	68	80	.	.
	100 mcg mRNA-1273 (18-55 years)	15	14	36.7	113	76	70	.	.
	100 mcg mRNA-1273 (18-55 years)	29	28	36.7	125	80	80	.	.
	100 mcg mRNA-1273 (18-55 years)	36	35	36.7	140	71	91	.	.
	100 mcg mRNA-1273 (18-55 years)	43	42	36.8	124	77	72	.	.
	100 mcg mRNA-1273 (18-55 years)	57	56	36.6	126	79	70	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	-1	-4	36.4	119	83	56	87	172.7
	100 mcg mRNA-1273 (18-55 years)	1	1	36.8	117	82	69	.	.
	100 mcg mRNA-1273 (18-55 years)	8	8	36.7	110	76	63	.	.
	100 mcg mRNA-1273 (18-55 years)	15	15	36.6	111	64	55	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	36.4	107	68	55	.	.
	100 mcg mRNA-1273 (18-55 years)	36	36	36.5	110	67	56	.	.
	100 mcg mRNA-1273 (18-55 years)	43	43	36.6	109	77	60	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-14	36.4	109	70	66	64.5	165.1
	250 mcg mRNA-1273 (18-55 years)	1	1	36.5	106	52	66	.	.
	250 mcg mRNA-1273 (18-55 years)	8	7	36.3	147 (Mild)	86	80	.	.
	250 mcg mRNA-1273 (18-55 years)	15	14	36.8	108	60	76	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	36.6	115	72	69	.	.
	250 mcg mRNA-1273 (18-55 years)	36	36	36.7	114	61	79	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-14	36.7	103	58	58	70.6	154.9

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	1	1	36.6	118	57	68	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.6	104	56	59	.	.
	250 mcg mRNA-1273 (18-55 years)	15	15	36.7	100	67	74	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	36.9	112	58	61	.	.
	250 mcg mRNA-1273 (18-55 years)	36	36	36.8	113	56	61	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-13	36.8	116	71	68	74.1	162.6
	250 mcg mRNA-1273 (18-55 years)	1	1	36.9	117	62	76	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	37.2	110	63	79	.	.
	250 mcg mRNA-1273 (18-55 years)	15	14	36.8	112	69	85	.	.
	250 mcg mRNA-1273 (18-55 years)	29	28	37.1	112	61	73	.	.
	250 mcg mRNA-1273 (18-55 years)	36	35	37.1	112	65	70	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-1	36.9	115	67	69	82.9	167.6
	25 mcg mRNA-1273 (56-70 years)	1	1	36.8	100	58	79	.	.
	25 mcg mRNA-1273 (56-70 years)	8	7	36.8	112	61	75	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	.	9	36.7	119	71	77	.	.
	25 mcg mRNA-1273 (56-70 years)	15	14	36.9	114	69	70	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	36.8	111	68	72	.	.
	25 mcg mRNA-1273 (56-70 years)	36	35	36.8	115	56	62	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-1	36.8	142 (Mild)	72	66	67.8	167.6
	25 mcg mRNA-1273 (56-70 years)	1	1	36.9	118	64	75	.	.
	25 mcg mRNA-1273 (56-70 years)	8	8	37.1	138	70	65	.	.
	25 mcg mRNA-1273 (56-70 years)	15	15	37	123	61	69	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	36.8	118	59	70	.	.
	25 mcg mRNA-1273 (56-70 years)	36	36	36.7	129	65	70	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-5	36.6	124	78	59	71.1	167.6
	100 mcg mRNA-1273 (56-70 years)	1	1	36.6	120	84	61	.	.
	100 mcg mRNA-1273 (56-70 years)	8	8	36.6	140	78	76	.	.
	100 mcg mRNA-1273 (56-70 years)	15	15	36.8	139	80	60	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	29	29	37.1	132	79	57	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.8	140	80	85	89.8	180.3
	25 mcg mRNA-1273 (56-70 years)	1	1	36.9	150 (Mild)	76	68	.	.
	25 mcg mRNA-1273 (56-70 years)	8	8	36.8	140	78	88	.	.
	25 mcg mRNA-1273 (56-70 years)	15	15	36.7	110	75	68	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	36.8	141 (Mild)	87	97	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.6	150 (Mild)	92 (Mild)	68	68.7	175.3
	25 mcg mRNA-1273 (56-70 years)	1	1	36.6	146 (Mild)	92 (Mild)	64	.	.
	25 mcg mRNA-1273 (56-70 years)	8	8	36.5	148 (Mild)	80	69	.	.
	25 mcg mRNA-1273 (56-70 years)	15	15	36.6	140	85	72	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	36.7	130	92 (Mild)	68	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.9	134	90	60	50.5	152.4
	100 mcg mRNA-1273 (56-70 years)	1	1	36.6	140	92 (Mild)	69	.	.
	100 mcg mRNA-1273 (56-70 years)	8	8	37	139	68	79	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	15	15	36.8	153 (Moderate)	87	73	.	.
	100 mcg mRNA-1273 (56-70 years)	29	30	36.8	130	70	84	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.9	116	72	68	86	182.9
	25 mcg mRNA-1273 (56-70 years)	1	1	36.9	114	73	69	.	.
	25 mcg mRNA-1273 (56-70 years)	8	8	36.6	115	62	76	.	.
	25 mcg mRNA-1273 (56-70 years)	15	15	36.9	117	69	77	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	36.9	127	77	72	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-5	36.7	101	58	58	64.7	171.5
	100 mcg mRNA-1273 (56-70 years)	1	1	36.8	96	60	64	.	.
	100 mcg mRNA-1273 (56-70 years)	8	8	36.9	91	63	69	.	.
	100 mcg mRNA-1273 (56-70 years)	15	15	36.6	103	57	69	.	.
	100 mcg mRNA-1273 (56-70 years)	29	29	36.8	105	70	61	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.5	141 (Mild)	70	74	95.2	195.6
	100 mcg mRNA-1273 (56-70 years)	1	1	36.6	129	74	75	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	8	9	36.2	130	79	81	.	.
	100 mcg mRNA-1273 (56-70 years)	15	14	36.6	137	71	76	.	.
	100 mcg mRNA-1273 (56-70 years)	29	28	36.8	128	84	78	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-10	36.9	144 (Mild)	88	75	92.7	185.7
	25 mcg mRNA-1273 (18-55 years)	1	1	36.9	132	88	77	.	.
	25 mcg mRNA-1273 (18-55 years)	8	8	37.3	122	80	60	.	.
	25 mcg mRNA-1273 (18-55 years)	15	16	36.9	130	76	88	.	.
	25 mcg mRNA-1273 (18-55 years)	29	30	36.8	142 (Mild)	80	72	.	.
	25 mcg mRNA-1273 (18-55 years)	36	38	36.9	128	82	62	.	.
	25 mcg mRNA-1273 (18-55 years)	43	44	36.6	130	84	64	.	.
	25 mcg mRNA-1273 (18-55 years)	57	59	36.8	120	80	80	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-9	36.6	106	74	65	56.2	158.7
	25 mcg mRNA-1273 (18-55 years)	1	1	37.1	104	65	72	.	.
	25 mcg mRNA-1273 (18-55 years)	8	8	37.2	101	64	88	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	15	15	36.8	114	69	99	.	.
	25 mcg mRNA-1273 (18-55 years)	29	30	37.1	102	67	84	.	.
	25 mcg mRNA-1273 (18-55 years)	36	38	37.2	113	79	89	.	.
	25 mcg mRNA-1273 (18-55 years)	43	44	36.9	103	58	86	.	.
	25 mcg mRNA-1273 (18-55 years)	57	59	37	111	72	83	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-9	36.6	114	69	56	62.9	172.6
	25 mcg mRNA-1273 (18-55 years)	1	1	37	120	63	56	.	.
	25 mcg mRNA-1273 (18-55 years)	8	8	36.7	111	65	67	.	.
	25 mcg mRNA-1273 (18-55 years)	15	15	36.7	112	63	65	.	.
	25 mcg mRNA-1273 (18-55 years)	29	30	37	106	56	58	.	.
	25 mcg mRNA-1273 (18-55 years)	36	38	37.2	118	61	57	.	.
	25 mcg mRNA-1273 (18-55 years)	43	44	36.7	108	53	62	.	.
	25 mcg mRNA-1273 (18-55 years)	57	59	36.6	114	64	65	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-9	36.6	105	65	80	57.8	164.6

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	1	1	36.4	128	61	87	.	.
	25 mcg mRNA-1273 (18-55 years)	8	8	36.4	113	57	82	.	.
	25 mcg mRNA-1273 (18-55 years)	15	15	36.6	103	65	69	.	.
	25 mcg mRNA-1273 (18-55 years)	29	30	36.9	114	59	77	.	.
	25 mcg mRNA-1273 (18-55 years)	36	38	36.4	115	52	76	.	.
	25 mcg mRNA-1273 (18-55 years)	43	44	37.1	109	52	81	.	.
	25 mcg mRNA-1273 (18-55 years)	57	59	36.8	100	66	78	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-7	36.7	139	97 (Moderate)	73	83.4	162.6
	100 mcg mRNA-1273 (18-55 years)	1	1	37.1	137	80	94	.	.
	100 mcg mRNA-1273 (18-55 years)	8	7	37	122	79	64	.	.
	100 mcg mRNA-1273 (18-55 years)	15	14	37.1	131	83	68	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	37.1	133	76	82	.	.
	100 mcg mRNA-1273 (18-55 years)	36	35	37	127	79	70	.	.
	100 mcg mRNA-1273 (18-55 years)	43	42	36.8	125	71	64	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	57	59	36.6	122	84	68	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-7	36.8	103	55	73	54.2	163.1
	100 mcg mRNA-1273 (18-55 years)	1	1	36.8	103	55	70	.	.
	100 mcg mRNA-1273 (18-55 years)	8	7	36.9	105	52	67	.	.
	100 mcg mRNA-1273 (18-55 years)	15	14	37	101	62	68	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	37.1	97	54	65	.	.
	100 mcg mRNA-1273 (18-55 years)	36	37	36.8	115	64	68	.	.
	100 mcg mRNA-1273 (18-55 years)	43	43	36.9	96	54	79	.	.
	100 mcg mRNA-1273 (18-55 years)	57	59	36.9	108	56	76	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-14	36.5	117	61	61	72.2	166.1
	25 mcg mRNA-1273 (18-55 years)	1	1	36.9	103	61	66	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.9	110	68	60	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	36.6	108	70	67	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.4	109	71	69	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	36	37	36.3	102	59	63	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	105	59	73	.	.
	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	111	72	66	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-14	36.3	121	70	61	107.9	182
	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	128	73	89	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.9	112	74	96	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	36.7	116	68	69	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	150 (Mild)	69	81	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	36.8	112	64	75	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.7	116	64	72	.	.
	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	115	68	81	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-6	36.4	139	66	55	81.6	169.2
	100 mcg mRNA-1273 (18-55 years)	1	1	37.2	138	71	72	.	.
	100 mcg mRNA-1273 (18-55 years)	8	7	37.1	130	65	68	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	15	14	37.1	118	60	69	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	36.9	120	61	70	.	.
	100 mcg mRNA-1273 (18-55 years)	36	37	37.1	117	56	68	.	.
	100 mcg mRNA-1273 (18-55 years)	43	43	37.1	114	72	80	.	.
	100 mcg mRNA-1273 (18-55 years)	57	58	37.2	109	52	73	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-6	36.8	114	69	84	72.5	166.6
	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	116	67	87	.	.
	100 mcg mRNA-1273 (18-55 years)	8	7	36.7	112	63	93	.	.
	100 mcg mRNA-1273 (18-55 years)	15	14	37	114	67	88	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	36.9	94	50	81	.	.
	100 mcg mRNA-1273 (18-55 years)	36	37	37.4	119	55	94	.	.
	100 mcg mRNA-1273 (18-55 years)	43	43	37	113	61	97	.	.
	100 mcg mRNA-1273 (18-55 years)	57	58	37.3	96	52	73	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-13	36.5	110	70	63	76.6	173.7

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	1	1	37.2	101	62	79	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	37	105	65	66	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	36.8	110	72	81	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	107	64	68	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	36.5	106	62	67	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	37	115	68	73	.	.
	25 mcg mRNA-1273 (18-55 years)	57	58	36.8	102	61	81	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-12	36.5	115	70	64	88.3	182.1
	25 mcg mRNA-1273 (18-55 years)	1	1	36.7	114	65	57	.	.
	25 mcg mRNA-1273 (18-55 years)	8	8					.	.
	25 mcg mRNA-1273 (18-55 years)	15	17	36.7	133	76	62	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.7	125	69	56	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	36.6	114	65	55	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.9	126	61	55	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	57	57	36.8	118	67	65	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-11	36.9	115	59	62	72.8	182.9
	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	110	58	60	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	113	73	73	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	36.9	104	60	68	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.9	115	57	72	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	36.4	116	53	82	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.4	117	68	73	.	.
	25 mcg mRNA-1273 (18-55 years)	57	57	36.8	114	65	70	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-11	36.8	107	72	77	91.5	174.2
	25 mcg mRNA-1273 (18-55 years)	1	1	36.7	111	72	81	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.8	121	85	95	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	36.7	117	71	75	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.7	115	71	73	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	36	36	36.6	118	73	84	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	125	76	98	.	.
	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	114	71	93	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-11	36.9	106	67	84	65.9	174.5
	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	124	80	82	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.8	107	70	97	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	37.6	110	67	80	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.7	104	64	78	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	37.1	111	71	79	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	100	58	91	.	.
	25 mcg mRNA-1273 (18-55 years)	57	56	37.1	111	71	93	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-10	37.3	129	79	75	71.5	177.4
	25 mcg mRNA-1273 (18-55 years)	1	1	36.7	131	79	78	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	123	76	77	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	15	14	36.7	115	72	74	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	108	62	83	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	36.7	106	59	81	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.6	117	72	83	.	.
	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	113	68	76	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-10	37.2	105	64	72	69.2	167.4
	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	104	55	72	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.7	110	65	85	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	37.1	108	66	80	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	99	58	70	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	36.7	110	60	78	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	110	60	84	.	.
	25 mcg mRNA-1273 (18-55 years)	57	58	36.6	118	57	79	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-25	37.2	142 (Mild)	82	56	76.7	185.7

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	133	69	90	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.7	132	60	63	.	.
	250 mcg mRNA-1273 (18-55 years)	15	15	37	128	68	62	.	.
	250 mcg mRNA-1273 (18-55 years)	29	28	36.4	125	75	63	.	.
	250 mcg mRNA-1273 (18-55 years)	36	35	36.8	120	64	65	.	.
	250 mcg mRNA-1273 (18-55 years)	43	43	36.3	122	71	67	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-10	36.9	131	72	72	68.8	179.5
	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	124	69	69	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	116	70	79	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	37	104	58	71	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	37.1	104	58	78	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	36.8	123	69	92	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.6	120	79	86	.	.
	25 mcg mRNA-1273 (18-55 years)	57	56	36.7	110	73	80	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	-1	-7	36.6	132	74	98	92.3	194.1
	25 mcg mRNA-1273 (18-55 years)	1	1	36.4	129	73	69	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	122	67	71	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	36.9	109	64	66	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.6	116	62	75	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	36.8	119	55	79	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.5	114	68	72	.	.
	25 mcg mRNA-1273 (18-55 years)	57	57	37.1	121	59	79	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-21	36.9	107	56	72	53	161
	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	116	72	70	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.8	111	75	70	.	.
	250 mcg mRNA-1273 (18-55 years)	15	16	36.6	116	72	77	.	.
	250 mcg mRNA-1273 (18-55 years)	29	28	36.5	117	76	68	.	.
	250 mcg mRNA-1273 (18-55 years)	36	35	36.7	110	69	82	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	43	43	36.6	122	68	95	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-25	37.2	136	96 (Moderate)	87	81.1	173.2
	250 mcg mRNA-1273 (18-55 years)	1	1	37	133	85	87	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	138	91 (Mild)	56	.	.
	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	138	83	64	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	37.7	137	83	84	.	.
	250 mcg mRNA-1273 (18-55 years)	36	36	37.2	130	84	75	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-20	37	120	62	90	53.2	159.8
	250 mcg mRNA-1273 (18-55 years)	1	1	37.4	114	62	88	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	118	72	88	.	.
	250 mcg mRNA-1273 (18-55 years)	15	16	36.5	131	72	89	.	.
	250 mcg mRNA-1273 (18-55 years)	29	28					.	.
	250 mcg mRNA-1273 (18-55 years)	36	35	36.7	111	55	84	.	.
	250 mcg mRNA-1273 (18-55 years)	43	43	36.7	122	72	82	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	-1	-19	37	127	66	77	75.6	176.2
	250 mcg mRNA-1273 (18-55 years)	1	1	37.4	120	69	99	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.8	131	75	90	.	.
	250 mcg mRNA-1273 (18-55 years)	15	16	37.1	116	67	86	.	.
	250 mcg mRNA-1273 (18-55 years)	29	28	37.1	130	65	83	.	.
	250 mcg mRNA-1273 (18-55 years)	36	35	37.1	129	67	74	.	.
	250 mcg mRNA-1273 (18-55 years)	43	43	37.1	123	75	71	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-24	36.9	142 (Mild)	85	53 (Mild)	80.1	167
	250 mcg mRNA-1273 (18-55 years)	1	1	37	124	68	75	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	131	75	74	.	.
	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	109	71	62	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	37.1	126	73	62	.	.
	250 mcg mRNA-1273 (18-55 years)	36	37	37.1	137	81	65	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-23	36.7	136	82	71	83.9	179.3

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	139	86	72	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	37.1	139	82	69	.	.
	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	131	74	71	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	36.9	118	66	77	.	.
	250 mcg mRNA-1273 (18-55 years)	36	37	37.3	124	76	71	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-23	36.4	102	61	65	52.1	152.7
	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	98	54	63	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	94	52	67	.	.
	250 mcg mRNA-1273 (18-55 years)	15	15	36.4	98	53	52 (Mild)	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	36.7	85 (Mild)	49	55	.	.
	250 mcg mRNA-1273 (18-55 years)	36	37	36.5	85 (Mild)	49	61	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-20	36.9	114	55	71	55.1	157.7
	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	107	63	68	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.6	114	65	66	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	113	65	83	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	36.8	116	61	77	.	.
	250 mcg mRNA-1273 (18-55 years)	36	37	37.1	105	59	75	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-16	36.7	109	69	76	87.6	173.2
	25 mcg mRNA-1273 (≥71 years)	1	1	36.7	110	68	81	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	36.7	112	78	72	.	.
	25 mcg mRNA-1273 (≥71 years)	15	15	36.5	120	78	65	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-16	36.9	131	60	58	47.4	153.9
	25 mcg mRNA-1273 (≥71 years)	1	1	36.3	145 (Mild)	70	57	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	36.6	149 (Mild)	68	53 (Mild)	.	.
	25 mcg mRNA-1273 (≥71 years)	15	16	36.7	140	70	58	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-16	37.1	122	77	71	84	179
	25 mcg mRNA-1273 (≥71 years)	1	1	36.6	128	77	74	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	36.8	112	72	73	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	15	15	36.7	113	68	71	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-16	37.1	143 (Mild)	66	75	62.5	171.7
	25 mcg mRNA-1273 (≥71 years)	1	1	36.8	141 (Mild)	76	68	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	37.1	129	68	70	.	.
	25 mcg mRNA-1273 (≥71 years)	15	15	36.7	140	76	67	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-13	37.1	112	73	74	83.5	174.9
	25 mcg mRNA-1273 (≥71 years)	1	1	36.9	136	79	72	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	37.1	130	84	80	.	.
	25 mcg mRNA-1273 (≥71 years)	15	16	36.9	134	75	78	.	.
	100 mcg mRNA-1273 (≥71 years)	-1	-21	36.4	121	69	55	83.7	169.1
	100 mcg mRNA-1273 (≥71 years)	1	1	36.8	109	57	62	.	.
	100 mcg mRNA-1273 (≥71 years)	8	9	36.6	115	55	62	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-13	36.9	126	84	77	78.3	171.1
	25 mcg mRNA-1273 (≥71 years)	1	1	36.6	148 (Mild)	92 (Mild)	62	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	8	9	36.9	128	87	89	.	.
	25 mcg mRNA-1273 (≥71 years)	15	16	36.7	136	85	94	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-13	36.8	124	65	86	73.8	180.1
	25 mcg mRNA-1273 (≥71 years)	1	1	36.9	135	81	82	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	36.5	124	66	75	.	.
	25 mcg mRNA-1273 (≥71 years)	15	16	36.7	120	74	71	.	.
	100 mcg mRNA-1273 (≥71 years)	-1	-14	36.9	112	56	78	67.4	152.5
	100 mcg mRNA-1273 (≥71 years)	1	1	36.4	122	58	66	.	.
	100 mcg mRNA-1273 (≥71 years)	8	9	36.5	103	54	65	.	.
	100 mcg mRNA-1273 (≥71 years)	15	16	36.9	109	67	71	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-14	37.1	117	68	71	53.3	163.6
	25 mcg mRNA-1273 (≥71 years)	1	1	36.6	120	69	68	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	36.6	128	73	69	.	.
	25 mcg mRNA-1273 (≥71 years)	15	16	36.4	122	68	65	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	-1	-14	37.2	125	68	74	78.3	164.6
	25 mcg mRNA-1273 (≥71 years)	1	1	37	139	63	79	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	36.9	117	62	63	.	.
	25 mcg mRNA-1273 (≥71 years)	15	16	36.8	114	59	77	.	.
	100 mcg mRNA-1273 (≥71 years)	-1	-20	36.9	143 (Mild)	78	73	60.7	156.9
	100 mcg mRNA-1273 (≥71 years)	1	1	37.3	145 (Mild)	75	72	.	.
	100 mcg mRNA-1273 (≥71 years)	8	8	37	148 (Mild)	75	73	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-12	36.7	146 (Mild)	70	53 (Mild)	80.8	178.2
	25 mcg mRNA-1273 (≥71 years)	1	1	36.8	119	64	62	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	36.6	136	66	56	.	.
	25 mcg mRNA-1273 (≥71 years)	15	15	36.9	129	71	58	.	.
	100 mcg mRNA-1273 (≥71 years)	-1	-12	36.8	122	67	68	68.4	162.8
	100 mcg mRNA-1273 (≥71 years)	1	1	36.5	117	58	72	.	.
	100 mcg mRNA-1273 (≥71 years)	8	9	36.5	128	69	65	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (≥71 years)	15	16	36.9	129	62	61	.	.
	100 mcg mRNA-1273 (≥71 years)	-1	-18	36.7	114	56	74	78.7	162.8
	100 mcg mRNA-1273 (≥71 years)	1	1	37.1	118	56	74	.	.
	100 mcg mRNA-1273 (≥71 years)	8	8	36.9	137	60	83	.	.
	100 mcg mRNA-1273 (≥71 years)	-1	-19	36.6	133	74	63	91.2	181.7
	100 mcg mRNA-1273 (≥71 years)	1	1	36.7	136	67	59	.	.
	100 mcg mRNA-1273 (≥71 years)	8	8	37.2	134	78	73	.	.
	100 mcg mRNA-1273 (≥71 years)	-1	-19	36.9	118	53	63	57.9	169.6
	100 mcg mRNA-1273 (≥71 years)	1	1	36.6	116	54	64	.	.
	100 mcg mRNA-1273 (≥71 years)	8	8	36.7	139	60	63	.	.
	100 mcg mRNA-1273 (≥71 years)	-1	-18	37.1	118	58	57	62.4	171
	100 mcg mRNA-1273 (≥71 years)	1	1	36.7	113	75	65	.	.
	100 mcg mRNA-1273 (≥71 years)	8	8	36.7	127	60	54 (Mild)	.	.
	100 mcg mRNA-1273 (≥71 years)	-1	-19	36.8	134	65	69	71.2	173.9

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (≥71 years)	1	1	36.6	119	58	60	.	.
	100 mcg mRNA-1273 (≥71 years)	8	8	36.8	132	70	57	.	.
	100 mcg mRNA-1273 (≥71 years)	-1	-17	37.2	144 (Mild)	83	78	80	165.4
	100 mcg mRNA-1273 (≥71 years)	1	1	37.1	132	71	75	.	.
	100 mcg mRNA-1273 (≥71 years)	8	8	36.9	142 (Mild)	74	78	.	.

**APPENDIX G1:
Listing of Protocol Deviations**

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
(b) (6)	250 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Subject unable to comply	No	No	No	subject instructed to eat and hydrate well before clinic visit	
	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Subject unable to comply	No	No	No	Not enough blood sample after multiple sticks. Subject will be advised to hydrate more.	
	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Other: Poor quality PBMC layer	No	No	No	Deviation not due to human error	
	100 mcg mRNA-1273 (18-55 years)	2	Too few aliquots obtained	Protocol procedure/assessment	28	Other: Poor quality PBMC layer	No	No	No	Deviation not due to human error	
	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Laboratory error	No	No	No	Rinse more CPT tubes to collect buffy coat layer	Suspected that the entire buffy coat wasn't collected

Appendix G1 (continued)
Listing of Protocol Deviations

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
(b) (6)	100 mcg mRNA-1273 (18-55 years)	2	Too few aliquots obtained	Protocol procedure/assessment	28	Other: Poor quality PBMC layer	No	No	No	Deviation not due to human error	
	100 mcg mRNA-1273 (18-55 years)	3	Too few aliquots obtained	Protocol procedure/assessment	34	Other: Poor quality PBMC layer	No	No	No	Deviation not due to human error	
	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Other: Poor quality PBMC layer	No	No	No	Deviation not due to human error	
	100 mcg mRNA-1273 (18-55 years)	2	Required procedure done incorrectly	Protocol procedure/assessment	55	Clinic error	No	No	No	Remind staff to double check the amount of blood collected.	
	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Other: Poor quality PBMC layer	No	No	No	Deviation not due to human error	
	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Laboratory error	No	No	No	Rinse more CPT tubes to collect buffy coat layer	Suspected that entire buffy coat wasn't collected

Appendix G1 (continued)
Listing of Protocol Deviations

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
(b) (6)	250 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Other: poor quality PBMC layer	No	No	No	Deviation not due to human error	
	25 mcg mRNA-1273 (56-70 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Other: Poor quality PBMC layer	No	No	No	Deviation not due to human error	
	100 mcg mRNA-1273 (56-70 years)	1	Missed visit/visit not conducted	Follow-up visit schedule	2	Subject unable to comply	No	No	No	Explained the importance of completing study visits to the subject	Once contact was made with the subject, the importance of completing each study visit within the time frame was reiterated and subject responded with an understanding.
	100 mcg mRNA-1273 (18-55 years)	1	Out of window visit	Follow-up visit schedule	46	Subject refusal	No	No	No	subjects will be reminded of importance of attending study visits within window	

Appendix G1 (continued)
Listing of Protocol Deviations

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
(b) (6)	100 mcg mRNA-1273 (18-55 years)	2	Required procedure done incorrectly	Protocol procedure/assessment	46	Subject refusal	No	No	No	subject moved out of state unexpectedly	
	100 mcg mRNA-1273 (18-55 years)	3	Required procedure done incorrectly	Protocol procedure/assessment	55	Subject refusal	No	No	No	subject moved out of state unexpectedly	
	250 mcg mRNA-1273 (18-55 years)	1	Required procedure not conducted	Protocol procedure/assessment	7	Clinic error	Yes, unsolicited AE	No	No	Coordinator re-trained on the importance of performing required procedures	
	25 mcg mRNA-1273 (18-55 years)	1	Other: non-required lab tests performed	Protocol procedure/assessment	1	Laboratory error	No	No	N/A	staff instructed to review study requirements and lab form prior to submission	lab staff did not fill out requisition form properly, so complete CBC was done rather than only study required tests.

Appendix G1 (continued)
Listing of Protocol Deviations

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
(b) (6)	25 mcg mRNA-1273 (18-55 years)	1	Required procedure done incorrectly	Protocol procedure/assessment	-14	Laboratory error	No	No	No	Lab staff will prepare tubes prior to study visit and double-check tubes again post-draw	Incorrect tube size was used during specimen collection. As a preventative measure, lab staff will prepare blood collection tubes prior to study visits and double-check again post-draw to confirm correct tubes were used.
	100 mcg mRNA-1273 (18-55 years)	1	Other: breach of confidentiality	Protocol procedure/assessment	-4	Clinic error	No	No	N/A	retraining of study staff	subject name was included on Quest requisition form, rather than study ID.
	25 mcg mRNA-1273 (18-55 years)	1	Required procedure not conducted	Protocol procedure/assessment	8	Investigator/study decision	No	No	N/A	Pt. under quarantine due to exposure, required procedures will be completed at V5	

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix G1 (continued)
Listing of Protocol Deviations

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
(b) (6)	25 mcg mRNA-1273 (18-55 years)	2	Other: V4 safety labs collected out of window	Protocol procedure/assessment	17	Subject unable to comply	No	No	N/A	Pt. unable to comply due to quarantine. V4 safety labs drawn at V5	
	250 mcg mRNA-1273 (18-55 years)	1	Required procedure done incorrectly	Treatment administration schedule	28	Subject illness	No	No	No	Will continue to attempt to complete visits per protocol	
	250 mcg mRNA-1273 (18-55 years)	1	Required procedure done incorrectly	Protocol procedure/assessment	1	Laboratory error	No	No	N/A	Lab staff will use a timer for visits requiring safety labs due to their shorter clot time window.	

**APPENDIX G2:
Listing of Non-Subject Deviations**

Study Site	Deviation Number	Deviation	Deviation Category	Reason for Deviation	Deviation Affected Product Stability?	Deviation Resolution	Comments
Emory Children's Center	1	Study product temperature excursion: EUC -80 freezer was out of range on April 17, 2020	Protocol procedure/assessment	Other:EUC -80 freezer had a malfunction.	Yes	A new -80 freezer has been purchased and in use.	The affected study product was immediately removed from EUC -80 freezer to EUH -80 freezer on April 17, 2020. The excursion was reported to DMID on April 18, 2020. DMID instructed to continue to use IP.

**APPENDIX H:
Listing of Pregnancies**

Table 1 – Maternal Information

No maternal information has been reported

Table 2 – Gravida and Para

No gravida and para have been reported.

Table 3 – Live Birth Outcomes

No live birth outcomes have been reported

Table 4 – Still Birth Outcomes

No maternal information has been reported

Table 5 – Spontaneous, Elective, or Therapeutic Abortion Outcomes

No spontaneous, elective, or therapeutic abortion outcomes have been reported